IDEAYA Biosciences Inc (STU:30J)
€ 29.6 0.8 (2.78%) Market Cap: 2.58 Bil Enterprise Value: 1.74 Bil PE Ratio: 0 PB Ratio: 2.34 GF Score: 28/100

IDEAYA Biosciences Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 16, 2023 / 03:00PM GMT
Release Date Price: €19.3 (+0.52%)
Greg Renza
RBC Capital Markets - Analyst

183 RBC Global Healthcare Conference. My name is Greg Renza, one of the Biotech Equity Research Analyst here at RBC. And we're pleased to be joined now by IDEAYA Biosciences. And joining us from the company is the President and CEO Yujiro Hata as well as the CFO Paul Stone. Gentlemen, thanks for joining us.

Yujiro Hata
IDEAYA Biosciences, Inc. - President & CEO

Okay, Greg, thank you so much for the kind introduction and for the opportunity to participate at this year's fireside chat. We'll look forward to the discussion.

Greg Renza
RBC Capital Markets - Analyst

Fantastic, I am as well. And there's certainly a lot going on with IDEAYA, a lot of interesting clinical and program developments as of late. So Yujiro, maybe we can just have to have you provide for those who are new to the IDEAYA story, just an intro to the company, the platform, and the lead assets (inaudible)

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot